Marissa LeBlanc

Marissa LeBlanc

Auto-generated profile, based on publicly available information

Marissa LeBlanc

Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway; Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MLMarissa LeBlanc
Marissa LeBlanc
VZVerena Zuber
Verena Zuber
WTWesley K. Thompson
Wesley K. Thompson
OAOle A. Andreassen
Ole A. Andreassen
AFArnoldo Frigessi
Arnoldo Frigessi
BABettina Kulle Andreassen
Bettina Kulle Andreassen
There is considerable evidence that many complex traits have a partially shared genetic basis, termed pleiotropy. It is therefore useful to consider integrating genome-wide association study (GWAS) data across several traits, usually at the summary statistic level. A major practical challenge arises when these GWAS have overlapping subjects. This is particularly an issue when estimating pleiotropy using methods that condition the significance of one trait on the signficance of a second, such as the covariate-modulated false discovery rate (cmfdr). We propose a method for correcting for sample overlap at the summary statistic level. We quantify the expected amount of spurious correlation between the summary statistics from two GWAS due to sample overlap, and use this estimated correlation in a simple linear correction that adjusts the joint distribution of test statistics from the two GWAS. The correction is appropriate for GWAS with case-control or quantitative outcomes. Our simulations and data example show that without correcting for sample overlap, the cmfdr is not properly controlled, leading to an excessive number of false discoveries and an excessive false discovery proportion. Our correction for sample overlap is effective in that it restores proper control of the false discovery rate, at very little loss in power. With our proposed correction, it is possible to integrate GWAS summary statistics with overlapping samples in a statistical framework that is dependent on the joint distribution of the two GWAS.

1 February 2012 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
MLMarissa LeBlanc
Marissa LeBlanc
BKBettina Kulle
Bettina Kulle
KSKjetil Sundet
Kjetil Sundet
IAIngrid Agartz
Ingrid Agartz
IMIngrid Melle
Ingrid Melle
OAOle A. Andreassen
Ole A. Andreassen

21 September 2020 in Acta Paediatrica
Verified
Journal Article
Open access
PDF file
KJKirsten Brunsvig Jarvis
Kirsten Brunsvig Jarvis
ALAndreas Lind
Andreas Lind
MLMarissa LeBlanc
Marissa LeBlanc
EREllen Ruud
Ellen Ruud
To contain the spread of the new severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes coronavirus disease 2019 (COVID‐19), the Norwegian government implemented lock‐down restrictions from 13.03.2020: schools, day cares and after‐school activities were closed, 2‐week quarantine was required following international travel, physical distancing (2 metres) was recommended and groups were restricted to 5 people.

17 September 2018 in BMC Proceedings
Verified
Journal Article
Open access
PDF file
HNHaakon E. Nustad
Haakon E. Nustad
CPChristian M. Page
Christian M. Page
ARAndrew H. Reiner
Andrew H. Reiner
MZManuela Zucknick
Manuela Zucknick
MLMarissa LeBlanc
Marissa LeBlanc
A Bayesian mixed model approach using integrated nested Laplace approximations (INLA) allows us to construct flexible models that can account for pedigree structure. Using these models, we estimate genome-wide patterns of DNA methylation heritability (h2), which are currently not well understood, as well as h2 of blood lipid measurements. We included individuals from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study with Infinium 450 K cytosine-phosphate-guanine (CpG) methylation and blood lipid data pre- and posttreatment with fenofibrate in families with up to three-generation pedigrees. For genome-wide patterns, we constructed 1 model per CpG with methylation as the response variable, with a random effect to model kinship, and age and gender as fixed effects. In total, 425,791 CpG sites pre-, but only 199,027 CpG sites posttreatment were found to have nonzero heritability. Across these CpG sites, the distributions of h2 estimates are similar in pre- and posttreatment (pre: median = 0.31, interquartile range [IQR] = 0.16; post: median = 0.34, IQR = 0.20). Blood lipid h2 estimates were similar pre- and posttreatment with overlapping 95% credibility intervals. Heritability was nonzero for treatment effect, that is, the difference between pre- and posttreatment blood lipids. Estimates for triglycerides h2 are 0.48 (pre), 0.42 (post), and 0.21 (difference); likewise for high-density lipoprotein cholesterol h2 the estimates are 0.61, 0.68, and 0.10. We show that with INLA, a fully Bayesian approach to estimate DNA methylation h2 is possible on a genome-wide scale. This provides uncertainty assessment of the estimates, and allows us to perform model selection via deviance information criterion (DIC) to identify CpGs with strong evidence for nonzero heritability.

23 February 2022 in Statistics in Medicine
Verified
Journal Article
Open access
MLMarissa LeBlanc
Marissa LeBlanc
CRCorina S. Rueegg
Corina S. Rueegg
NBNural Bekiroğlu
Nural Bekiroğlu
TETonya M. Esterhuizen
Tonya M. Esterhuizen
MFMorten W. Fagerland
Morten W. Fagerland
MZManuela Zucknick
Manuela Zucknick

17 September 2018 in BMC Genetics
Verified
Journal Article
Open access
PDF file
HNHaakon E. Nustad
Haakon E. Nustad
MAMarcio Augusto Afonso de Almeida
Marcio Augusto Afonso de Almeida
ACAngelo J. Canty
Angelo J. Canty
MLMarissa LeBlanc
Marissa LeBlanc
CPChristian M. Page
Christian M. Page
PMPhillip Melton
Phillip Melton
Longitudinal data and repeated measurements in epigenome-wide association studies (EWAS) provide a rich resource for understanding epigenetics. We summarize 7 analytical approaches to the GAW20 data sets that addressed challenges and potential applications of phenotypic and epigenetic data. All contributions used the GAW20 real data set and employed either linear mixed effect (LME) models or marginal models through generalized estimating equations (GEE). These contributions were subdivided into 3 categories: (a) quality control (QC) methods for DNA methylation data; (b) heritability estimates pretreatment and posttreatment with fenofibrate; and (c) impact of drug response pretreatment and posttreatment with fenofibrate on DNA methylation and blood lipids. Two contributions addressed QC and identified large statistical differences with pretreatment and posttreatment DNA methylation, possibly a result of batch effects. Two contributions compared epigenome-wide heritability estimates pretreatment and posttreatment, with one employing a Bayesian LME and the other using a variance-component LME. Density curves comparing these studies indicated these heritability estimates were similar. Another contribution used a variance-component LME to depict the proportion of heritability resulting from a genetic and shared environment. By including environmental exposures as random effects, the authors found heritability estimates became more stable but not significantly different. Two contributions investigated treatment response. One estimated drug-associated methylation effects on triglyceride levels as the response, and identified 11 significant cytosine-phosphate-guanine (CpG) sites with or without adjusting for high-density lipoprotein. The second contribution performed weighted gene coexpression network analysis and identified 6 significant modules of at least 30 CpG sites, including 3 modules with topological differences pretreatment and posttreatment. Four conclusions from this GAW20 working group are: (a) QC measures are an important consideration for EWAS studies that are investigating multiple time points or repeated measurements; (b) application of heritability estimates between time points for individual CpG sites is a useful QC measure for DNA methylation studies; (c) drug intervention demonstrated strong epigenome-wide DNA methylation patterns across the 2 time points; and (d) new statistical methods are required to account for the environmental contributions of DNA methylation across time. These contributions demonstrate numerous opportunities exist for the analysis of longitudinal data in future epigenetic studies.